<DOC>
	<DOCNO>NCT02021656</DOCNO>
	<brief_summary>This study evaluate antiviral efficacy ledipasvir ( LDV ) /sofosbuvir ( SOF ) fixed-dose combination ( FDC ) treatment-naive treatment-experienced participant chronic genotype 1 Hepatitis C Virus ( HCV ) infection . Participants receive 12 week treatment continue assessment 24-week follow-up period .</brief_summary>
	<brief_title>Efficacy Safety Ledipasvir/Sofosbuvir Fixed-Dose Combination Participants With Chronic Genotype 1 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Key Willing able provide write informed consent HCV RNA ≥ 10^4 IU/mL screen HCV treatmentnaïve ( HCV genotype 1 ) , define prior exposure interferon ( IFN ) approve experimental HCVspecific directacting antiviral agent ; OR HCV treatmentexperienced medical record include sufficient detail prior IFNbased treatment allow categorization prior response either intolerant , nonresponder , experienced viral breakthrough relapse . HCV infection document antiHCV antibody test , genotyping test , liver biopsy Key Pregnant nurse female male pregnant female partner Chronic liver disease nonHCV etiology Current prior history clinicallysignificant illness ( HCV ) Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>